Cover Image
市場調查報告書

老年癡呆症相關的癡呆症:開發中產品分析

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 265422
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
老年癡呆症相關的癡呆症:開發中產品分析 Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 73 Pages
簡介

所謂老年癡呆症是造成記憶·思考·行動障礙之癡呆症的一種。常見的症狀有憂鬱症、社會性自閉、心情低落、性急、攻擊性、自制力低落等。致病危險因子有年齡,家族病史,輕度認知障礙(MCI)。主要的治療方法包含膽鹼酯酶抑製劑,健康生活習慣等。

本報告提供老年癡呆症相關的癡呆症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

老年癡呆症相關的癡呆症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

老年癡呆症相關的癡呆症:企業開發中的治療藥

老年癡呆症相關的癡呆症:大學/機關研究中的治療藥

老年癡呆症相關的癡呆症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

老年癡呆症相關的癡呆症:企業開發中的產品

老年癡呆症相關的癡呆症:大學/機關研究中的產品

老年癡呆症相關的癡呆症的治療藥的開發企業

  • Adamas Pharmaceuticals, Inc.
  • AgeneBio Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Boehringer Ingelheim GmbH
  • Chase Pharmaceuticals Corporation
  • Eisai
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • MediPost Co., Ltd.
  • Neurodyn Inc.

老年癡呆症相關的癡呆症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

老年癡呆症相關的癡呆症:最近的開發平台趨勢

老年癡呆症相關的癡呆症:暫停中的計劃

老年癡呆症相關的癡呆症:開發中止的產品

老年癡呆症相關的癡呆症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8589IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides an overview of the Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline landscape.

Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life. Alzheimer's is a type of dementia. Symptoms include depression, social withdrawal, mood swings, irritability and aggressiveness and loss of inhibitions. Risk factors include age, family history and mild cognitive impairment. Treatment includes cholinesterase inhibitors and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia Associated With Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Unknown stages are 6, 2 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively for Dementia Associated With Alzheimer's Disease.

Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dementia Associated With Alzheimer's Disease Overview
  • Therapeutics Development
    • Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview
    • Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis
  • Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies
  • Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes
  • Dementia Associated With Alzheimer's Disease - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Dementia Associated With Alzheimer's Disease - Products under Development by Companies
  • Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes
  • Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals, Inc.
    • AgeneBio Inc.
    • Amarantus Bioscience Holdings, Inc.
    • Boehringer Ingelheim GmbH
    • Chase Pharmaceuticals Corporation
    • Eisai Co., Ltd.
    • H. Lundbeck A/S
    • MediPost Co., Ltd.
  • Dementia Associated With Alzheimer's Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (donepezil hydrochloride + solifenacin succinate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-409306 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-2609 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltoprazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gln-1062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levetiracetam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LUAF-20513 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neurostem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • salicylamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dementia Associated With Alzheimer's Disease - Dormant Projects
  • Dementia Associated With Alzheimer's Disease - Discontinued Products
  • Dementia Associated With Alzheimer's Disease - Product Development Milestones
    • Featured News & Press Releases
      • Aug 31, 2016: Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation
      • Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer's Association International Conference
      • Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering & Investment Forum
      • Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website
      • Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression
      • Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference
      • Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer's Disease
      • Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia
      • Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer's Dementia
      • Jan 28, 2015: AgeneBio Receives Grant from Alzheimer's Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer's Dementia
      • May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories
      • May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016
  • Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by AgeneBio Inc., H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dementia Associated With Alzheimer's Disease - Dormant Projects, H2 2016
  • Dementia Associated With Alzheimer's Disease - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016
  • Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top